The emerging Norwegian biotech company Cytovation AS has identified a potent therapeutically-active peptide, CyPep-H1, which has potential in the treatment of cutaneous warts and cancer and should enter clinical studies in the second half of 2018 with the help of NOK30m (€3.2m) raised in a private funding round led by a group of local investors.
Cytovation was founded in 2001 as a conduit for developing interesting technology, and the company was reconfigured in its present form in 2014 when the peptide research started to bear fruit, said CEO Kjell-Inge Arnevig in a recent interview with Scrip
Researchers have been trying to identify peptides and proteins that might act as anti-infectious agents, anticancer antigens or oncolytic peptides for some time, and Cytovation decided a number of years ago to pursue this in a systematic way